Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

May 31, 2004

Study Completion Date

February 29, 2008

Conditions
Lung Cancer
Interventions
DRUG

Celecoxib

400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.

DRUG

Docetaxel

On day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days

Trial Locations (1)

48201-1379

Barbara Ann Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT00030420 - Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter